Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Immunology
Fator do impacto: 1.404 FI de cinco anos: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472

Volume 40, 2020 Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v21.i1-3.170
11 pages

Clinical Translation of Peptide-Based Vaccine Trials: The HER-2/neu Model

Mary L. Disis
Division of Oncology, Box 356527, University of Washington, Seattle, WA 98195-6527
Keith L. Knutson
Division of Oncology, University of Washington, Seattle, WA
Douglas G. McNeel
Division of Oncology, University of Washington, Seattle, WA
Donna Davis
Division of Oncology, University of Washington, Seattle, WA
Kathy Schiffman
Division of Oncology, University of Washington, Seattle, WA


In the development of targeted cancer immunotherapies, the choice of antigen is obviously critical to the design of any therapeutic strategy, but particularly so for tumor vaccines, which must distinguish malignant cells from normal cells. Investigations a decade ago focused on mutated tumor antigens, or viral tumor antigens, with the belief that these foreign or abnormal proteins would be best recognized by the host immune system.Within the last 10 years, however, several tumor antigens have been identified on the basis of recognition by infiltrating T cells in tumor samples. Studies on melanoma, in particular, have revealed that in addition to some mutated tumor antigens, several aberrantly expressed normal proteins, as well as tissue-specific differentiation factors, are recognized by the host immune system. Similar studies in other solid tumors have revealed that certain oncogenes overexpressed in malignant cells, such as p53 and HER-2/neu, are also recognized by host T cells. Our group has been investigating the HER-2/neu oncogenic protein as a vaccine target in patients with HER-2/neu–overexpressing cancers. However, several issues unique to the design of human clinical trials of cancer vaccines must be addressed when translating preclinical experiments to human clinical trials. First, HER-2/neu protein expression can vary depending on the tumor type. How would expression differences impact clinical trial design? Secondly, what are the issues in clinical trial design that are critical to the successful execution of a phase I study of a peptide-based vaccine? Thirdly, what types and amounts of clinical material are readily available for immunologic analysis and can be obtained with little distress and risk to the patients enrolled in the study? Finally, what steps must be implemented for a laboratory assay to evolve to meet the validation criteria needed for application as an immunologic monitoring tool?

Articles with similar content:

Tumor-Specific Immune Response: Current In Vitro Analyses May Not Reflect the In Vivo Immune Status
Critical Reviews™ in Immunology, Vol.18, 1998, issue 1-2
Philippe Kourilsky, Florence Faure, Jos Even
HER-2/neu Oncogenic Protein: Issues in Vaccine Development
Critical Reviews™ in Immunology, Vol.18, 1998, issue 1-2
Mary L. Disis, Martin A. Cheever
T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy
Critical Reviews™ in Immunology, Vol.39, 2019, issue 2
David M. Kranz, Preeti Sharma
Tumor Metastasis to Brain: Role of Endothelial Cells, Neurotrophins, and Paracrine Growth Factors
Critical Reviews™ in Oncogenesis, Vol.5, 1994, issue 5
Philip Cavanaugh, Motowo Nakajima, Garth L. Nicolson, Dario Marchetti, Libin Jia, David G. Menter, Jun-ichi Hamada, John Herrmann, Zhong Yun
Cellular Mucins: Targets for Immunotherapy
Critical Reviews™ in Immunology, Vol.14, 1994, issue 3-4
Vasso Apostolopoulos , Ian F. C. McKenzie